The consensus price target for CRISPR Therapeutics AG (NASDAQ:CRSP) has been adjusted from $72.75 to $65, reflecting changes in financial performance and industry developments. Despite a quarterly ...

Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro ...

Mammoth Biosciences researchers have developed NanoCas, an ultracompact CRISPR nuclease, demonstrating its ability to perform ...

By Balambal Suryanarayanan CRISPR-Cas9 is a repurposed gene editing tool that allows scientists to cut, replace, and insert pieces of DNA in precise regions along the strand. Courtesy of NIH Image ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

The kit was created during their time as undergraduates under the mentorship of Qi, a CRISPR/Cas9 researcher. Qi believes that college students are critical in making biotechnologies within the ...

Comprehensively, genome-wide CRISPR/Cas9 knockout (inhibition ... receptor (VEGFR), fibroblast growth factor receptor (FGFR), MET proto-oncogene (MET), and KIT proto-oncogene (KIT) (Regad, 2015). They ...

1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-5900 USA 2Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical ...